---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-050880"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T01:29:09.952868+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Viridian Therapeutics appoints Christopher Cain to board; Peter Harwin resigns effective March 10

## Summary
- Christopher Cain (Director of Research, Fairmount Funds Management) named Class I director and chair of Nominating and Corporate Governance Committee.
- Peter Harwin resigned from the board effective March 10, 2025, with no disagreement with the company.
- Cain also joins the Audit Committee and Science & Technology Committee; standard director compensation applies.
- Cain previously served at Samsara BioCapital, Apple Tree Partners, RA Capital Management, and BioCentury.

## SEC filing metadata
- accession: 0001193125-25-050880
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312525050880/0001193125-25-050880-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312525050880/d937334d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-050880
- JSON: https://secwatch.observer/filing/0001193125-25-050880.json
- Plain text: https://secwatch.observer/filing/0001193125-25-050880.txt

## Key facts
- Executive change
  Peter Harwin resigned as Director at Viridian Therapeutics, Inc.\DE.
  - Action: resigned
  - Role: Director
  source text: On March 5, 2025, Peter Harwin, a member of the Board, notified the Company of his decision to resign as a member of the Board effective as of March 10, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312525050880/0001193125-25-050880-index.htm
- Executive change
  Christopher Cain was appointed as Class I Director at Viridian Therapeutics, Inc.\DE.
  - Action: appointed
  - Role: Class I Director
  source text: appointed Christopher Cain, Ph.D., the Director of Research at Fairmount Funds Management LLC, to serve as a Class I director of the Company, chairperson of the Nominating and Corporate Governance Committee, and member of the Audit Committee and Science & Technology Committee, effective as of March 10, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312525050880/0001193125-25-050880-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.